Recent

% | $
Quotes you view appear here for quick access.

Bergamo Acquisition Corp. Message Board

  • investking99 investking99 Apr 10, 2013 1:24 PM Flag

    BGMO Acquiries majority ownership in VistaGem

    April 10, 2013 08:47 ET
    VistaGen Announces $36 Million Strategic Financing Agreement
    Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs
    SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 10, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (PINKSHEETS: BGMO), a global diversified investment holding company.
    Under the terms of the agreement, Bergamo's European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share. The Company's self-placed strategic financing does not include warrants or any investment banking fees. The transaction is scheduled to close on or before April 30, 2013. At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen's Common Stock.
    VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe™ 3D and LiverSafe™ 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportuniti

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • VistaGen Therapeutics, Inc., a California corporation, was incorporated in California in May 1998 (VistaGen California). We have been located in Northern California continuously since that time. Currently (and since April 2007) our headquarters (both laboratories and executive offices) are located at 384 Oyster Point Boulevard, Building No. 8, in South San Francisco, California, located near Genentech. Our SEC filings, IRS filings, audited financial statements, web site, press releases, material contracts (including our current real property lease) and the like all concur with that fact. Any statements by anyone to the contrary are false, defamatory and material misrepresentations of fact.

      The details of our May 2011 reverse merger-based going public transaction have been fully disclosed in multiple SEC filings over the past nearly two years, as well as in our audited financial statements. We are current on all required SEC filings, as our each of our officers and directors. As reported to the SEC, as a result of our reverse merger going public transaction, in May 2011 VistaGen California became and remains a wholly-owned subsidiary of VistaGen Therapeutics, Inc., a Nevada corporation, which is a publicly held and fully-reporting company with hundreds of stockholders, including Platinum Long Term Growth Fund.

      The multiple investments in VistaGen by Platinum Long Term Growth Fund, beginning in 2007 and continuing through last month, also have been exhaustively reported in our press releases, SEC filings and audited financial statements. Any statement by anyone that Platinum Long Term Growth Fund does not exist and/or has not made multiple material investments in VistaGen since 2007 are false, defamatory and material misrepresentations of fact

      Sentiment: Strong Buy

      • 3 Replies to elephanthunter11
      • It's not a matter of if BGMO will purchase 72% of VSTA it just a matter of when.

        We know the hold period of the of the initial profit of $88 million earned from the first US $500 will be up in a few months, but obviously BGMO managaent believe the purchase of VSTA will happen before then.

        Quote:
        In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada

        Sentiment: Strong Buy

      • LiverSafe 3D™

        In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, we are developing engineered cell lines and enhancing protocols to control the differentiation of pluripotent stem cells into normal, mature, human liver cells for use in a novel liver cell-based bioassay system for predicting liver toxicity and metabolism issues in connection with our drug rescue activities. We refer to this novel human liver cell-based bioassay system as LiverSafe 3D™. We plan to complete development of LiverSafe 3D in early-2013.

        Sentiment: Strong Buy

      • $VSTA Business Description
        VistaGen Therapeutics Inc. is biotechnology company harnessing the revolutionary power of human pluripotent stem cell technology for drug rescue and cell therapy.

        VistaGen's drug rescue activities involve the combination of its human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of small molecule drug candidates that pharmaceutical companies have discontinued during preclinical development ("put on the shelf") due to heart or liver toxicity, despite promising efficacy data. VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube(TM), is based on directed differentiation (development) of human pluripotent stem cells into multiple types of mature cells. With heart cells produced from stem cells, VistaGen has developed CardioSafe 3D(TM), a three-dimensional biological assay (screening) system the company believes is capable of predicting the human cardiac effects, both toxic and non-toxic, of new drug candidates, long before they are tested in humans. VistaGen's immediate goal is to leverage CardioSafe 3D(TM) to generate and monetize a pipeline of small molecule drug candidates through drug rescue collaborations. VistaGen intends to expand its drug rescue capabilities by introducing LiverSafe 3D(TM), a human liver cell-based toxicity and metabolism bioassay system. In collaboration with Dr. Gordon Keller, recently named a "Top 25 Transformational Canadian" for his pioneering stem cell research and technology, VistaGen is also advancing pilot preclinical development of large market cell therapy programs, including cartilage, heart and liver repair

        Sentiment: Strong Buy

    • more lies rip-off kings

      Sentiment: Strong Sell

      • 1 Reply to camino482000
      • Here are the main points investors should considered:

        • The company trades at a $17.5 million market cap (based on outstanding shares as of 2/12/13)
        • Over a 15-year period, the company has obtained and deployed over $53 million
        • The investment represented by the strategic financing announced today is 67.9% of this $53 million value
        • The transaction is expected to close by the end of this month (compare this to the 15 years it took VistaGen to obtain $53 million)

        It doesn't take much math to project the rate at which VistaGen will accelerate and expand its stem cell technology-based drug rescue, predictive toxicology, and drug metabolism programs.

        Sentiment: Strong Buy